Quarterly report pursuant to Section 13 or 15(d)

Note 16 - Segments (Tables)

v3.8.0.1
Note 16 - Segments (Tables)
9 Months Ended
Sep. 30, 2017
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Three Months Ended September 30, 201
7
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept sales revenue
:
                               
United State
s
  $
    $
    $
    $
 
Internationa
l
   
     
     
     
 
Tc99m tilmanocept license revenu
e
   
     
     
     
 
Grant and other revenu
e
   
210,479
     
13,190
     
     
223,669
 
Total revenu
e
   
210,479
     
13,190
     
     
223,669
 
Cost of goods sold, excluding depreciation and amortizatio
n
   
     
     
     
 
Research and development expenses
,
excluding depreciation and amortization
   
734,539
     
140,008
     
     
874,547
 
Selling, general and administrative expenses
,
excluding depreciation and amortization
(1)
   
     
13,359
     
1,671,022
     
1,684,381
 
Depreciation and amortization
(2
)
   
     
     
50,326
     
50,326
 
Loss from operations
(3
)
   
(524,060
)
   
(140,177
)
   
(1,721,348
)
   
(2,385,585
)
Other income
(4
)
   
     
     
69,071
     
69,071
 
Income tax benefi
t
   
175,496
     
46,942
     
553,312
     
775,750
 
Net loss from continuing operation
s
   
(348,564
)
   
(93,235
)
   
(1,098,965
)
   
(1,540,764
)
Income from discontinued operations, net of ta
x
   
5,399
     
     
     
5,399
 
Gain on sale of discontinued operations, net of ta
x
   
145,877
     
     
     
145,877
 
Net los
s
   
(197,288
)
   
(93,235
)
   
(1,098,965
)
   
(1,389,488
)
Total assets, net of depreciation and amortization
:
                               
United State
s
   
14,675,489
     
10,591
     
7,835,426
     
22,521,506
 
Internationa
l
   
82,334
     
     
1,867
     
84,201
 
Capital expenditures
   
     
     
23,247
     
23,247
 
Three Months Ended
September
30
, 2016
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept
sales revenue:
                               
United States
  $
    $
    $
    $
 
International
   
17,601
     
     
     
17,601
 
Tc99m tilmanocept
license revenue
   
1,295,625
     
     
     
1,295,625
 
Grant and other revenue
   
500,628
     
10,346
     
     
510,974
 
Total revenue
   
1,813,854
     
10,346
     
     
1,824,200
 
Cost of goods sold, excluding depreciation and amortization
   
2,889
     
     
     
2,889
 
Research and development expenses, excluding depreciation and amortization
   
671,777
     
247,664
     
     
919,441
 
Selling, general and administrative expenses, excluding depreciation and amortization
(
1
)
   
     
27,758
     
1,694,073
     
1,721,831
 
Depreciation and amortization
(
2
)
   
     
     
89,849
     
89,849
 
Income (l
oss) from operations
(
3
)
   
1,139,188
     
(265,076
)
   
(1,783,922
)
   
(909,810
)
Other
expenses 
(
4
)
   
     
     
(851,637
)
   
(851,637
)
Net
income (loss) from continuing operations
   
1,139,188
     
(265,076
)
   
(2,635,559
)
   
(1,761,447
)
Income
from discontinued operations, net of tax
   
1,701,911
     
     
     
1,701,911
 
Net
income (loss)
   
2,841,099
     
(265,076
)
   
(2,635,559
)
   
(59,536
)
Total assets, net of depreciation and amortization:
                               
United States
   
4,950,756
     
9,356
     
6,080,567
     
11,040,679
 
International
   
148,224
     
     
697
     
148,921
 
Capital expenditures
   
     
     
     
 
Nine
Months Ended
September
30, 2017
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept sales revenue:
                               
United States
  $
    $
    $
    $
 
International
   
     
     
     
 
Tc99m tilmanocept license revenue
   
100,000
     
     
     
100,000
 
Grant and other revenue
   
1,200,216
     
115,082
     
     
1,315,298
 
Total revenue
   
1,300,216
     
115,082
     
     
1,415,298
 
Cost of goods sold, excluding depreciation and amortization
   
     
     
     
 
Research and development expenses, excluding depreciation and amortization
   
2,255,842
     
509,853
     
     
2,765,695
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
19,342
     
8,789,728
     
8,809,070
 
Depreciation and amortization
(2)
   
     
     
197,655
     
197,655
 
L
oss from operations
(3)
   
(955,626
)
   
(414,113
)
   
(8,987,383
)
   
(10,357,122
)
Other expenses
(4)
   
     
     
(1,061,190
)
   
(1,061,190
)
Income tax benefit
   
323,149
     
140,034
     
3,397,972
     
3,861,156
 
Net loss from continuing operations
   
(632,477
)
   
(274,079
)
   
(6,650,601
)
   
(7,557,156
)
Loss from discontinued operations, net of tax
   
(332,838
)
   
     
     
(332,838
)
Gain on sale of discontinued operations, net of tax
   
86,894,000
     
     
     
86,894,000
 
Net income (loss)
   
85,928,685
     
(274,079
)
   
(6,650,601
)
   
79,004,006
 
Total assets, net of depreciation and amortization:
                               
United States
   
14,675,489
     
10,591
     
7,835,426
     
22,521,506
 
International
   
82,334
     
     
1,867
     
84,201
 
Capital expenditures
   
     
     
31,417
     
31,417
 
Nine
Months Ended
September
30
, 2016
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept sales revenue:
                               
United States
  $
    $
    $
    $
 
International
   
30,800
     
     
     
30,800
 
Tc99m tilmanocept license revenue
   
1,795,625
     
     
     
1,795,625
 
Grant and other revenue
   
2,051,622
     
61,798
     
     
2,113,420
 
Total revenue
   
3,878,047
     
61,798
     
     
3,939,845
 
Cost of goods sold, excluding depreciation and amortization
   
5,185
     
     
     
5,185
 
Research and development expenses, excluding depreciation and amortization
   
4,410,133
     
600,790
     
     
5,010,923
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
31,590
     
5,542,034
     
5,573,624
 
Depreciation and amortization
(2)
   
     
     
258,999
     
258,999
 
Loss from operations
(3)
   
(537,271
)
   
(570,582
)
   
(5,801,033
)
   
(6,908,886
)
Other income, excluding equity in loss of R-NAV, LLC
(4)
   
     
     
1,664,265
     
1,664,265
 
Equity in loss of R-NAV, LLC
   
     
     
(15,159
)
   
(15,159
)
Net loss from continuing operations
   
(537,271
)
   
(570,582
)
   
(4,151,927
)
   
(5,259,780
)
Loss from discontinued operations, net of tax
   
(5,167,312
)
   
     
     
(5,167,312
)
Net loss
   
(5,704,583
)
   
(570,582
)
   
(4,151,927
)
   
(10,427,092
)
Total assets, net of depreciation and amortization:
                               
United States
   
4,950,756
     
9,356
     
6,080,567
     
11,040,679
 
International
   
148,224
     
     
697
     
148,921
 
Capital expenditures
   
     
     
1,847
     
1,847